About Biomarkers Consortium

The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making

Consortium Partners

This exceptional group of organizations has aligned to further efforts dedicated to the discovery, development and the seeking of regulatory approval for biological markers (i.e. biomarkers) that support new drug development, preventive medicine and medical diagnostics.

Working to support research and guide clinical practice is the main goal of The Biomarkers Consortium. This collaborative effort ensures that the voice of all stakeholders involved in biomarker research is heard and contributes to strides made in support of promising initiatives undertaken by The Consortium in areas such as cancer, immunity & inflammation, metabolic disorders and neuroscience.

Become a part of the growing list of contributing members from industry, foundations, professional associations and patient advocacy organizations, working together along with our government colleagues from the National Institutes of Health and U.S. Food and Drug Administration to achieve a new era of predictive, preventive and personalized medicine through biomarker research.

FDA logo
NIH Logo
For Profit
abbive logo
adaptive logo
ADX logo
Alector logo
alkermes logo
amgen logo
amra logo
astellas logo
astrazeneca logo
Bayer logo
bio-rad logo
Biogen logo
C2N logo
celgene logo
Gates Ventures
genetech logo
Genmab logo
Ikena logo
Invicro logo
Jazz Pharma logo
johnson and johnson logo
labcorp logo
Lilly logo
lundbeck logo
merck logo
Neurimmune 260px.png
Novartis logo
Nordic Bioscience logo
olink logo
oxford logo
Path AI Logo
ProMis logo
regeneron logo
sage therapeutics logo
sanofi logo
sengenics logo
takeda logo
UCB logo
Not-for-Profit Organizations
alzheimers logo
Alzheimers Drug Discovery Foundation logo
American Diabetes Association logo
American Heart Association logo
Arthritis Foundation logo
Association for Molecular Pathology logo
The Association for Frontotemporal Degeneration logo
Bright Focus Foundation logo
CHDI logo
Chrons & Colitis Foundation logo
Fredrick National Laboratory logo
Multiple Myeloma logo
National Dairy Council logo
PhRMA logo
Radiological Society of North America logo
Society for Immunotherapy of Cancer
Sjogrens Syndrome foundation logo

Founding Partners

The Biomarkers Consortium was established by the Foundation for the National Institutes of Health, the National Institutes of Health, the U.S. Food and Drug Administration and Pharmaceutical Research and Manufacturers of America. In addition, the Centers for Medicare & Medicaid Services and Biotechnology Industry Organization have been instrumental in the implementation and organization of The Biomarkers Consortium.


Policies and Procedures
The policies and procedures established by The Biomarkers Consortium include:
Membership Manual
Conflict of Interest Policy
Confidentiality Policy
Antitrust Policy and Guidelines
General Intellectual Property and Data Sharing Principles
Principles and Policies on Selection and Award of Grants or Contracts Funded by FNIH under The Biomarkers Consortium
Publication Guidelines

For more information about the policies and procedures of The Consortium, please contact us at biomarkers@fnih.org.


Key Resources

Publications about the Biomarkers Consortium: 


American Society for Clinical Pharmacology & Therapeutics (ASCPT): "How To Develop and Qualify Biomarkers: Biomarker Consortium Perspective" Speaker: Joseph P. Menetski, Ph.D., Associate Vice President of Research Partnerships, FNIH


FNIH Biomarkers Consortium - Beta Cell Project "A New Tool for Diabetes Research"